DEF: Encision Inc. Details Executive Compensation, Board Nominees, and Governance for 2025 Annual Meeting

Encision Inc. has filed its definitive proxy statement outlining proposals for its upcoming Annual Meeting, including the election of four directors, ratification of auditors, and advisory votes on executive compensation.

Summary

• Encision Inc. will hold its Annual Meeting of Shareholders on August 21, 2025, at 9:00 A.M. Mountain Time, at its offices in Boulder, CO.
• Shareholders will vote on four key proposals: the election of four directors, the ratification of GreenGrowth CPAs as independent public accountants, a non-binding advisory resolution on executive officer compensation, and a non-binding advisory vote on the frequency of future executive compensation votes.
• As of the record date, June 23, 2025, there were 11,879,645 shares of common stock outstanding and entitled to vote.
• The company reported a Net Loss of $(220.2) thousand for fiscal year 2025, an improvement from $(691.8) thousand in fiscal year 2024 and $(323.9) thousand in fiscal year 2023.
• Total Shareholder Return (TSR) for an initial $100 investment on March 31, 2021, was $70.00 by March 31, 2025, down from $75.00 in fiscal year 2024.
• CEO Gregory J. Trudel's total compensation was $303,136 in FY2025, including $253,753 in salary and $49,383 in option awards.
• The board recommends voting for the election of all four director nominees, for the ratification of GreenGrowth CPAs, for the advisory resolution on executive compensation, and for a 'three years' frequency for future advisory votes on executive compensation.
• The 2014 Equity Incentive Plan has 349,000 shares still available for grant as of March 31, 2025, out of 1,100,000 shares reserved.

Sentiment

Score: 6

Explanation: The document presents a mixed financial picture with a reduced net loss (positive) but a decline in TSR (negative). Governance is generally strong with independent committees, but there are notable issues with late Section 16(a) filings. Overall, it's a routine proxy statement with some positive financial trends and some compliance shortcomings.

Positives

• Net Loss decreased significantly from $(691.8) thousand in fiscal year 2024 to $(220.2) thousand in fiscal year 2025, indicating an improvement in financial performance.
• Three of the four board members (Robert H. Fries, Vern D. Kornelsen, and Patrick W. Pace, M.D.) are independent, and the audit, compensation, and nominating committees are composed entirely of independent directors, promoting strong corporate governance.
• The company has adopted a Code of Ethics and an insider trading policy that prohibits derivative transactions, pledging, and hedging of company stock by executive officers and directors.
• Equity grant timing is not connected to the release of material non-public information, indicating a commitment to fair and transparent compensation practices.

Negatives

• Total Shareholder Return (TSR) decreased from $75.00 in FY2024 to $70.00 in FY2025, indicating a decline in shareholder value over the measurement period.
• Several executive officers and directors had late Section 16(a) filings during the fiscal year ended March 31, 2025, including Brian Jackman, Vern Kornelsen, Gregory Trudel (two late Forms 4 each), Patrick Pace (three late Forms 4), Robert Fries, Mala Ray (one late Form 4 each), and Brandon Shepard (one late initial Form 3), indicating compliance issues.
• Audit fees increased from $48,500 in FY2024 (Gries & Associates, LLC) to $74,750 in FY2025 (GreenGrowth CPAs).

Risks

• The board's compensation committee believes there are no compensation policies and programs that give rise to risks reasonably likely to have a material adverse effect on the company.
• Certain transactions in company securities (such as purchases and sales of publicly traded put and call options, and short sales) create a heightened compliance risk or could create the appearance of misalignment between management and stockholders.
• Securities held in a margin account or pledged as collateral may be sold without consent if the owner fails to meet a margin call or defaults on the loan, creating a risk of sales when an officer or director is aware of material, non-public information or is otherwise not permitted to trade.

Future Outlook

The Board of Directors will consider the results of the non-binding advisory votes on executive compensation and its frequency when making future decisions regarding executive compensation programs. The company intends to satisfy disclosure requirements for amendments to or waivers from its Code of Ethics by posting such information on its website.

Management Comments

• The Board of Directors believes that the decision as to who should serve as Chairman of the Board and/or Chief Executive Officer and whether the offices should be combined or separated is the proper responsibility of the board.
• The Board of Directors and the Compensation Committee believe that the compensation paid to our executive officers is effective in achieving our compensation objectives.
• The Board of Directors believes that a vote every three years for the frequency of future advisory votes on executive compensation is consistent with the Company's efforts to engage in an ongoing dialogue with shareholders on executive compensation and corporate governance matters.

Industry Context

This DEF 14A filing is a standard corporate governance document for a publicly traded company, focusing on shareholder meeting proposals, executive compensation, and board structure. The company operates in the surgical devices marketplace, as indicated by the CEO's background, but the document does not provide specific industry trends or competitive analysis.

Comparison to Industry Standards

• The company's board of directors adheres to the independence criteria under applicable New York Stock Exchange, Inc. (NYSE) rules, with three out of four directors qualifying as independent, which aligns with good governance practices for public companies.
• The audit, compensation, and nominating committees are composed entirely of independent directors, which is a strong governance practice consistent with NYSE listing standards and best practices for public companies.
• The company's executive compensation program aims to align executive compensation with the shareholder experience (i.e., stock price) through stock option grants, a common practice in the industry to incentivize performance.

Management Changes

Corporate Governance

Related Party Transactions

• During the 2025 fiscal year, $40,727 was paid in compensation to an entity controlled by board member Robert H. Fries for financial and tax consulting services provided to the company.

Stakeholder Impact

• Shareholders: Will vote on key governance matters, including director elections, auditor ratification, and executive compensation, directly influencing the company's future direction and oversight. The decline in TSR impacts shareholder returns.
• Executive Officers: Compensation details are disclosed, and future compensation will be influenced by advisory votes. Employment agreements provide for base salary, bonuses, and severance.
• Directors: Compensation for independent directors is detailed, and their roles in governance and oversight are outlined. Compliance issues with Section 16(a) filings could reflect negatively on individual directors.
• Employees: The 2014 Equity Incentive Plan allows for awards to employees, aligning their interests with company performance.

Next Steps

• Shareholders to vote on director elections, auditor ratification, executive compensation, and frequency of future executive compensation votes at the Annual Meeting on August 21, 2025.
• The Board of Directors and Compensation Committee will review and consider the voting results from the advisory votes on executive compensation when making future decisions.
• The company will continue to evaluate its communication process with shareholders and may adopt additional procedures.
• Audit-related expenses incurred by GreenGrowth CPAs for the fiscal year ended March 31, 2025, will be paid in fiscal year March 31, 2026, and reported in next year's proxy statement.

Key Dates

Keywords

Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Shareholder Vote, SEC Filing, Medical Devices, Surgical Devices, Encision Inc.